凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
莱茵生物(002166)公告正文

莱茵生物:2019年第一季度报告全文

公告日期 2019-04-29
股票简称:莱茵生物 股票代码:002166
                桂林莱茵生物科技股份有限公司 2019 年第一季度报告全文




桂林莱茵生物科技股份有限公司

     2019 年第一季度报告




        2019 年 04 月




                                                                  1
                                    桂林莱茵生物科技股份有限公司 2019 年第一季度报告全文




                         第一节 重要提示


    公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真

实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和

连带的法律责任。

    所有董事均已出席了审议本次季报的董事会会议。

    公司负责人秦本军、主管会计工作负责人郑辉及会计机构负责人(会计主管

人员)张为鹏声明:保证季度报告中财务报表的真实、准确、完整。




                                                                                      2
                                                           桂林莱茵生物科技股份有限公司 2019 年第一季度报告全文




                                       第二节 公司基本情况

一、主要会计数据和财务指标

公司是否需追溯调整或重述以前年度会计数据
□ 是 √ 否

                                            本报告期                  上年同期              本报告期比上年同期增减

营业收入(元)                                  104,485,780.72           111,482,325.48                         -6.28%

归属于上市公司股东的净利润(元)                 10,709,457.75            18,291,677.28                        -41.45%

归属于上市公司股东的扣除非经常性损
                                                 10,660,691.18            17,843,157.61                        -40.25%
益的净利润(元)

经营活动产生的现金流量净额(元)                -90,038,057.53            12,804,279.37                       -803.19%

基本每股收益(元/股)                                     0.02                       0.04                      -50.00%

稀释每股收益(元/股)                                     0.02                       0.04                      -50.00%

加权平均净资产收益率                                     0.96%                    1.73%                         -0.77%

                                                                                            本报告期末比上年度末增
                                           本报告期末                 上年度末
                                                                                                         减

总资产(元)                                  2,117,842,409.13         2,122,029,854.59                         -0.20%

归属于上市公司股东的净资产(元)              1,122,069,182.19         1,113,665,614.29                         0.75%

非经常性损益项目和金额
√ 适用 □ 不适用
                                                                                                              单位:元

                         项目                              年初至报告期期末金额                   说明

计入当期损益的政府补助(与企业业务密切相关,按照国家统
                                                                        100,734.55
一标准定额或定量享受的政府补助除外)

除上述各项之外的其他营业外收入和支出                                     34,667.33

减:所得税影响额                                                         86,635.31

合计                                                                     48,766.57                  --

对公司根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义界定的非经常性损益项目,以及把《公
开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常性损益项目界定为经常性损益的项目,应
说明原因
□ 适用 √ 不适用
公司报告期不存在将根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义、列举的非经常性损益
项目界定为经常性损益的项目的情形。




                                                                                                                         3
                                                           桂林莱茵生物科技股份有限公司 2019 年第一季度报告全文


二、报告期末股东总数及前十名股东持股情况表

1、普通股股东总数和表决权恢复的优先股股东数量及前 10 名股东持股情况表

                                                                                                             单位:股

                                                 报告期末表决权恢复的优先股股
报告期末普通股股东总数                  50,110                                                                     0
                                                 东总数(如有)

                                              前 10 名股东持股情况

                                                                   持有有限售条件的股           质押或冻结情况
   股东名称         股东性质      持股比例          持股数量
                                                                         份数量            股份状态         数量

秦本军           境内自然人            18.63%         81,476,544            61,107,408 质押                53,620,000

姚新德           境内自然人             7.86%         34,361,643            25,771,232 质押                34,361,417

梁定志           境外自然人             4.77%         20,874,447

中央汇金资产管
                 国有法人               4.46%         19,491,600
理有限责任公司

蒋安明           境内自然人             3.43%         15,000,000

蒋小三           境内自然人             3.43%         15,000,000

蒋俊             境内自然人             3.43%         15,000,000

易红石           境内自然人             2.46%         10,763,257

蒋新荣           境内自然人             1.41%          6,169,285

陈兴华           境内自然人             1.03%          4,506,100                         质押               4,330,000

                                       前 10 名无限售条件股东持股情况

                                                                                                股份种类
          股东名称                           持有无限售条件股份数量
                                                                                        股份种类           数量

梁定志                                                                  20,874,447 人民币普通股            20,874,447

秦本军                                                                  20,369,136 人民币普通股            20,369,136

中央汇金资产管理有限责任公司                                            19,491,600 人民币普通股            19,491,600

蒋安明                                                                  15,000,000 人民币普通股            15,000,000

蒋小三                                                                  15,000,000 人民币普通股            15,000,000

蒋俊                                                                    15,000,000 人民币普通股            15,000,000

易红石                                                                  10,763,257 人民币普通股            10,763,257

姚新德                                                                   8,590,411 人民币普通股             8,590,411

蒋新荣                                                                   6,169,285 人民币普通股             6,169,285

陈兴华                                                                   4,506,100 人民币普通股             4,506,100

上述股东关联关系或一致行动的 1、公司股东秦本军与蒋安明、蒋小三、蒋俊为兄弟关系,属于一致行动人。2、姚新德
说明                           系公司董事,与秦本军、蒋安明、蒋小三、蒋俊均不存在一致行动关系。3、其他股东


                                                                                                                        4
                                                         桂林莱茵生物科技股份有限公司 2019 年第一季度报告全文


                               之间关系不详。

公司前 10 名普通股股东、前 10 名无限售条件普通股股东在报告期内是否进行约定购回交易
□ 是 √ 否
公司前 10 名普通股股东、前 10 名无限售条件普通股股东在报告期内未进行约定购回交易。


2、公司优先股股东总数及前 10 名优先股股东持股情况表

□ 适用 √ 不适用




                                                                                                           5
                                                                      桂林莱茵生物科技股份有限公司 2019 年第一季度报告全文




                                                 第三节 重要事项

一、报告期主要财务数据、财务指标发生变动的情况及原因

√ 适用 □ 不适用

1、资产负债表项目变动情况(单位:人民币元)
       项目           期末余额           期初余额          增减比例                         变动原因

    货币资金          51,031,473.25      31,589,704.19        61.54% 主要系报告期末新增银行贷款入账所致

    预付款项           6,881,432.50       3,138,758.12       119.24% 主要系报告期植物提取业务预付原辅料款增加所致

    在建工程           5,287,309.55       3,928,468.46        34.59% 主要系报告期设备改造支出增加所致

  长期待摊费用           101,441.82           150,801.55     -32.73% 主要系报告期装修工程摊销所致

 其他非流动资产        3,294,157.77       2,531,810.27        30.11% 主要系报告期支付设备款增加并从“预付账款”重分类所致

    短期借款         469,700,000.00     345,000,000.00        36.14% 主要系报告期短期银行贷款增加所致

  应付职工薪酬         1,875,141.49       8,478,173.57       -77.88% 主要系报告期发放上年计提的绩效工资及奖金所致

   其他应付款         11,214,262.06      19,573,053.01       -42.71% 主要系报告期支付上年预提费用所致

    应付利息             211,639.58           577,130.20     -63.33% 主要系报告期支付上年计提的按季支付的银行利息所致

  其他综合收益         4,117,058.58       6,422,948.43       -35.90% 主要系报告期外币报表折算差额所致



2、利润表项目变动情况(单位:人民币元)
     项目           本年发生额         上年发生额          增减比例                          变动原因

                                                                       主要系报告期BT项目进入收尾阶段,收入减少导致税金及附
  税金及附加         38,187.16          136,712.38           -72.07%
                                                                       加相应减少

   管理费用          10,433,061.26       8,212,396.08         27.04% 主要系报告期人员工资性费用等增加所致

   财务费用           4,947,642.70       2,645,970.84         86.99% 主要系报告期随银行贷款增加利息支出增加所致

 资产减值损失          -305,314.12            -87,394.30    -249.35% 主要系报告期销售回款冲回多提坏账准备所致

   其他收益             100,330.50            449,507.00     -77.68% 主要系报告期计入当期损益的政府补助减少所致

  营业外收入             34,667.33             13,060.40     165.44% 主要系报告期产品保险赔偿等增加所致

  所得税费用          2,549,805.28       4,102,707.51        -37.85% 主要系报告期因应纳税所得额减少所致



3、现金流量表项目变动情况(单位:人民币元)
            项目                 本年发生额        上年发生额         增减比例                    变动原因




                                                                                                                        6
                                                           桂林莱茵生物科技股份有限公司 2019 年第一季度报告全文


                                                                         主要系报告期支付原辅料款增加、以及上年报告
 经营活动现金流量净额   -90,038,057.53    12,804,279.37       -803.19%
                                                                         期BT项目回款1.45亿元所致

 投资活动现金流量净额    -10,087,525.32   -44,380,320.33        77.27% 主要系报告期设备支出减少所致

 筹资活动现金流量净额    119,706,499.60    26,266,158.06       355.74% 主要系报告期银行贷款增加所致




二、重要事项进展情况及其影响和解决方案的分析说明

√ 适用 □ 不适用

     1、公司第一期和第二期员工持股计划出售事项

     公司于2019年1月14日召开第五届董事会第十一次会议,会议审议通过了《关于拟出售第一期和第二

期员工持股计划的议案》,公司董事会同意将第一期和第二期员工持股计划所持公司股份全部出售。截至

本报告披露日,公司第一期和第二期员工持股计划已通过大宗交易方式全部出售。

     2、控股股东一致行动人增持情况

     2019年1月14日至2019年1月15日,控股股东秦本军先生及其一致行动人蒋安明先生、蒋小三先生、蒋

俊先生通过大宗交易方式受让了公司第一期、第二期员工持股计划所持有的合计17,156,219股股份,占公

司总股本的3.92%。本次增持后,控股股东及其一致行动人的合计持股比例达到公司总股本的28.92%。

     3、公司向全体股东配售股份

     2019年3月7日,公司收到中国证监会发行审核委员会《关于核准桂林莱茵生物科技股份有限公司配股

的批复》。

     截至本报告披露日,公司已向截至2019年4月8日(股权登记日)在中国证券登记结算有限责任公司深

圳分公司登记在册的莱茵生物全体A股股东,按照每10股配售3股的比例配售人民币普通股(A股),共计

可配售股份总数为131,184,408股,发行价格为3.77元/股。A股配股发行已完成,公司A股股东有效认购数

量为127,933,378股,募集资金482,308,835.06元,扣除发行费用11,942,978.01元,本次发行募集资金净额

为470,365,857.05元。

     4、转让莱茵康尔1%股权事项

     2019年2月27日,公司与桂林莱茵康尔生物技术有限公司(以下简称“莱茵康尔”)签订股权转让协

议。鉴于莱茵康尔目前未开展实际运营,资产状况未发生重大变化,交易双方同意以北京中同华资产评估

有限公司对莱茵康尔出具的中同华评报字(2017)第1034号《资产评估报告书》的评估价值为参考,协商

确定本次股权转让价款为人民币396万元。本次股权转让实施完成后,公司不再持有莱茵康尔的股份,但

其仍属于公司的关联方。

                                                                                                               7
                                                           桂林莱茵生物科技股份有限公司 2019 年第一季度报告全文


     5、BT项目合同

     BT项目的建设已进入收尾阶段,2019年BT项目主要工作为工程收尾,以及将与项目业主方保持有效

沟通,推动项目回购款的早日收回,支持公司主业发展。

     截至2019年3月31日,BT项目累计完成工程产值约18.3亿元,已累计收到回购款13.584亿元。2019年1

季度,莱茵投资实现营业收入28,209,864.96元,净利润12,571,096.50元。(未经审计)

          重要事项概述               披露日期                       临时报告披露网站查询索引

公司第一期和第二期员工持股                         巨潮资讯网 www.cninfo.com.cn<《关于公司第一期和第二期员工持
                             2019 年 01 月 16 日
计划出售事项                                       股计划出售完毕暨终止的公告》(公告编号:2019-004)

                                                   巨潮资讯网 www.cninfo.com.cn《关于公司控股股东及其一致行动
控股股东一致行动人增持       2019 年 01 月 16 日
                                                   人增持公司股份的公告》(公告编号:2019-005)

                                                   巨潮资讯网 www.cninfo.com.cn《关于配股申请获得中国证监会核
公司向全体股东配售股份       2019 年 03 月 09 日
                                                   准批复的公告》(公告编号:2019-007)

                                                   巨潮资讯网 www.cninfo.com.cn《BT 项目合同实施进展公告》(公
BT 项目                      2019 年 04 月 11 日
                                                   告编号:2019-014)

股份回购的实施进展情况
□ 适用 √ 不适用
采用集中竞价方式减持回购股份的实施进展情况
□ 适用 √ 不适用


三、公司实际控制人、股东、关联方、收购人以及公司等承诺相关方在报告期内超期未履行
完毕的承诺事项

□ 适用 √ 不适用
公司报告期不存在公司实际控制人、股东、关联方、收购人以及公司等承诺相关方在报告期内超期未履行完毕的承诺事项。


四、对 2019 年 1-6 月经营业绩的预计

√ 适用 □ 不适用
2019 年 1-6 月预计的经营业绩情况:
净利润为正,同比下降 50%以上

2019 年 1-6 月归属于上市公司股东的净利润变动幅度                        -60.00%      至                 -30.00%

2019 年 1-6 月归属于上市公司股东的净利润变动区间(万元)                2,889.06     至                 5,055.86

2018 年 1-6 月归属于上市公司股东的净利润(万元)                                                        7,226.66

                                                       公司预计 2019 年 1-6 月植物提取业务的业绩较上年同期取得
业绩变动的原因说明                                     一定增长,但因 BT 项目较上年同期确认的收入大幅减少,
                                                       净利润大幅降低,对报告期经营业绩影响较大。




                                                                                                                   8
                                                        桂林莱茵生物科技股份有限公司 2019 年第一季度报告全文


五、以公允价值计量的金融资产

□ 适用 √ 不适用


六、违规对外担保情况

□ 适用 √ 不适用
公司报告期无违规对外担保情况。


七、控股股东及其关联方对上市公司的非经营性占用资金情况

□ 适用 √ 不适用
公司报告期不存在控股股东及其关联方对上市公司的非经营性占用资金。


八、报告期内接待调研、沟通、采访等活动登记表

□ 适用 √ 不适用
公司报告期内未发生接待调研、沟通、采访等活动。




                                                                                                          9
                                                       桂林莱茵生物科技股份有限公司 2019 年第一季度报告全文




                                         第四节 财务报表

一、财务报表

1、合并资产负债表

编制单位:桂林莱茵生物科技股份有限公司
                                                                                                       单位:元

                  项目                     2019 年 3 月 31 日                  2018 年 12 月 31 日

流动资产:

    货币资金                                              51,031,473.25                        31,589,704.19

    结算备付金

    拆出资金

    交易性金融资产

    以公允价值计量且其变动计入当期
损益的金融资产

    衍生金融资产

    应收票据及应收账款                                    87,008,511.55                       112,578,842.98

      其中:应收票据                                        4,460,031.00

               应收账款                                   82,548,480.55                       112,578,842.98

    预付款项                                                6,881,432.50                        3,138,758.12

    应收保费

    应收分保账款

    应收分保合同准备金

    其他应收款                                            17,560,439.29                        16,870,718.32

      其中:应收利息                                            221,540.08                           221,540.08

               应收股利

    买入返售金融资产

    存货                                               1,090,764,559.64                     1,088,532,774.25

    合同资产

    持有待售资产

    一年内到期的非流动资产

    其他流动资产                                          43,016,696.87                        39,109,647.13

流动资产合计                                            1,296,263,113.10                    1,291,820,444.99



                                                                                                             10
                                     桂林莱茵生物科技股份有限公司 2019 年第一季度报告全文


非流动资产:

    发放贷款和垫款

    债权投资

    可供出售金融资产                                                       179,721,550.03

    其他债权投资

    持有至到期投资

    长期应收款

    长期股权投资

    其他权益工具投资                   175,761,954.08

    其他非流动金融资产

    投资性房地产                         5,572,662.17                        5,612,174.75

    固定资产                           560,892,505.91                      567,270,232.24

    在建工程                             5,287,309.55                        3,928,468.46

    生产性生物资产

    油气资产

    使用权资产

    无形资产                            51,352,890.46                       51,677,998.03

    开发支出

    商誉

    长期待摊费用                          101,441.82                          150,801.55

    递延所得税资产                      19,316,374.27                       19,316,374.27

    其他非流动资产                       3,294,157.77                        2,531,810.27

非流动资产合计                         821,579,296.03                      830,209,409.60

资产总计                             2,117,842,409.13                    2,122,029,854.59

流动负债:

    短期借款                           469,700,000.00                      345,000,000.00

    向中央银行借款

    拆入资金

    交易性金融负债

    以公允价值计量且其变动计入当期
损益的金融负债

    衍生金融负债

    应付票据及应付账款                 347,165,213.88                      469,414,187.84

    预收款项                             2,311,302.20                        3,192,875.77




                                                                                        11
                             桂林莱茵生物科技股份有限公司 2019 年第一季度报告全文


    卖出回购金融资产款

    吸收存款及同业存放

    代理买卖证券款

    代理承销证券款

    应付职工薪酬                 1,875,141.49                        8,478,173.57

    应交税费                     6,146,344.99                        8,605,545.39

    其他应付款                  11,214,262.06                       19,573,053.01

      其中:应付利息               211,639.58                         577,130.20

               应付股利

    应付手续费及佣金

    应付分保账款

    合同负债

    持有待售负债

    一年内到期的非流动负债      11,001,272.68                       11,001,272.68

    其他流动负债                13,701,766.86                       13,295,080.82

流动负债合计                   863,115,304.16                      878,560,189.08

非流动负债:

    保险合同准备金

    长期借款

    应付债券

      其中:优先股

               永续债

    租赁负债

    长期应付款

    长期应付职工薪酬

    预计负债

    递延收益                   131,798,863.99                      128,878,863.99

    递延所得税负债                777,293.43                          777,293.43

    其他非流动负债

非流动负债合计                 132,576,157.42                      129,656,157.42

负债合计                       995,691,461.58                    1,008,216,346.50

所有者权益:

    股本                       437,281,362.00                      437,281,362.00

    其他权益工具



                                                                               12
                                                       桂林莱茵生物科技股份有限公司 2019 年第一季度报告全文


      其中:优先股

               永续债

    资本公积                                             261,669,420.58                       261,669,420.58

    减:库存股

    其他综合收益                                            4,117,058.58                        6,422,948.43

    专项储备

    盈余公积                                              41,642,337.56                        41,642,337.56

    一般风险准备

    未分配利润                                           377,359,003.47                       366,649,545.72

归属于母公司所有者权益合计                             1,122,069,182.19                     1,113,665,614.29

    少数股东权益                                                81,765.36                            147,893.80

所有者权益合计                                         1,122,150,947.55                     1,113,813,508.09

负债和所有者权益总计                                    2,117,842,409.13                    2,122,029,854.59


法定代表人:秦本军                   主管会计工作负责人:郑辉                      会计机构负责人:张为鹏


2、母公司资产负债表

                                                                                                       单位:元

                  项目                     2019 年 3 月 31 日                  2018 年 12 月 31 日

流动资产:

    货币资金                                              43,581,814.61                        26,512,195.37

    交易性金融资产

    以公允价值计量且其变动计入当期
损益的金融资产

    衍生金融资产

    应收票据及应收账款                                   152,758,422.98                       168,288,721.61

      其中:应收票据                                        4,460,031.00

               应收账款                                  148,298,391.98                       168,288,721.61

    预付款项                                                5,666,201.88                        2,327,726.91

    其他应收款                                           199,626,099.19                       189,510,409.35

      其中:应收利息

               应收股利

    存货                                                 541,327,187.93                       524,173,657.21

    合同资产

    持有待售资产


                                                                                                             13
                                     桂林莱茵生物科技股份有限公司 2019 年第一季度报告全文


    一年内到期的非流动资产

    其他流动资产                        31,703,770.80                       27,801,422.09

流动资产合计                           974,663,497.39                      938,614,132.54

非流动资产:

    债权投资

    可供出售金融资产                                                       179,256,481.73

    其他债权投资

    持有至到期投资

    长期应收款

    长期股权投资                        52,363,304.59                       51,913,304.59

    其他权益工具投资                   175,761,954.08

    其他非流动金融资产

    投资性房地产                         5,572,662.17                        5,612,174.75

    固定资产                           392,126,492.90                      397,160,753.51

    在建工程                             5,287,309.55                        3,928,468.46

    生产性生物资产

    油气资产

    使用权资产

    无形资产                            50,632,790.46                       50,957,898.03

    开发支出

    商誉

    长期待摊费用

    递延所得税资产                      21,004,299.35                       21,004,299.35

    其他非流动资产                       3,294,157.77                        2,531,810.27

非流动资产合计                         706,042,970.87                      712,365,190.69

资产总计                             1,680,706,468.26                    1,650,979,323.23

流动负债:

    短期借款                           469,700,000.00                      345,000,000.00

    交易性金融负债

    以公允价值计量且其变动计入当期
损益的金融负债

    衍生金融负债

    应付票据及应付账款                  75,075,003.59                      159,979,581.79

    预收款项                             1,216,026.20                        1,107,413.15




                                                                                       14
                             桂林莱茵生物科技股份有限公司 2019 年第一季度报告全文


    合同负债

    应付职工薪酬                  413,981.21                         4,198,317.67

    应交税费                      543,910.47                         3,830,137.16

    其他应付款                   4,678,307.82                       12,044,282.45

      其中:应付利息               211,639.58                         577,130.20

               应付股利

    持有待售负债

    一年内到期的非流动负债      11,001,272.68                       11,001,272.68

    其他流动负债

流动负债合计                   562,628,501.97                      537,161,004.90

非流动负债:

    长期借款

    应付债券

      其中:优先股

               永续债

    租赁负债

    长期应付款

    长期应付职工薪酬

    预计负债

    递延收益                   131,148,863.99                      128,228,863.99

    递延所得税负债                745,943.42                          745,943.42

    其他非流动负债

非流动负债合计                 131,894,807.41                      128,974,807.41

负债合计                       694,523,309.38                      666,135,812.31

所有者权益:

    股本                       437,281,362.00                      437,281,362.00

    其他权益工具

      其中:优先股

               永续债

    资本公积                   261,669,420.59                      261,669,420.59

    减:库存股

    其他综合收益

    专项储备

    盈余公积                    41,642,337.56                       41,642,337.56



                                                                               15
                                               桂林莱茵生物科技股份有限公司 2019 年第一季度报告全文


    未分配利润                                   245,590,038.73                      244,250,390.77

所有者权益合计                                   986,183,158.88                      984,843,510.92

负债和所有者权益总计                           1,680,706,468.26                    1,650,979,323.23


3、合并利润表

                                                                                             单位:元

                   项目                    本期发生额                       上期发生额

一、营业总收入                                     104,485,780.72                    111,482,325.48

    其中:营业收入                                 104,485,780.72                    111,482,325.48

          利息收入

          已赚保费

          手续费及佣金收入

二、营业总成本                                      91,428,048.01                     89,541,570.14

    其中:营业成本                                  67,168,733.99                     69,645,373.90

          利息支出

          手续费及佣金支出

          退保金

          赔付支出净额

          提取保险合同准备金净额

          保单红利支出

          分保费用

          税金及附加                                      38,187.16                       136,712.38

          销售费用                                      6,864,750.16                     7,032,895.29

          管理费用                                  10,433,061.26                        8,212,396.08

          研发费用                                      2,280,986.86                     1,955,615.95

          财务费用                                      4,947,642.70                     2,645,970.84

            其中:利息费用                              4,431,949.11                     1,878,333.33

                     利息收入                             35,890.41                        11,864.16

          资产减值损失                                  -305,314.12                        -87,394.30

          信用减值损失

    加:其他收益                                         100,330.50                       449,507.00

        投资收益(损失以“-”号填列)                       404.05

    其中:对联营企业和合营企业的投资收益

        汇兑收益(损失以“-”号填列)



                                                                                                   16
                                               桂林莱茵生物科技股份有限公司 2019 年第一季度报告全文


    净敞口套期收益(损失以“-”号填列)

    公允价值变动收益(损失以“-”号填列)

         资产处置收益(损失以“-”号填列)

三、营业利润(亏损以“-”号填列)                  13,158,467.26                     22,390,262.34

    加:营业外收入                                      34,667.33                        13,060.40

    减:营业外支出                                                                       14,638.09

四、利润总额(亏损总额以“-”号填列)              13,193,134.59                     22,388,684.65

    减:所得税费用                                   2,549,805.28                      4,102,707.51

五、净利润(净亏损以“-”号填列)                  10,643,329.31                     18,285,977.14

  (一)按经营持续性分类

    1.持续经营净利润(净亏损以“-”号填列)        10,643,329.31                     18,285,977.14

    2.终止经营净利润(净亏损以“-”号填列)

  (二)按所有权属分类

    1.归属于母公司所有者的净利润                    10,709,457.75                     18,291,677.28

    2.少数股东损益                                     -66,128.44                         -5,700.14

六、其他综合收益的税后净额                          -2,305,889.85                     -1,650,205.61

  归属母公司所有者的其他综合收益的税后
                                                    -2,305,889.85                     -1,650,205.61
净额

    (一)不能重分类进损益的其他综合收益

           1.重新计量设定受益计划变动额

       2.权益法下不能转损益的其他综合收益

           3.其他权益工具投资公允价值变动

           4.企业自身信用风险公允价值变动

           5.其他

    (二)将重分类进损益的其他综合收益              -2,305,889.85                     -1,650,205.61

         1.权益法下可转损益的其他综合收益

           2.其他债权投资公允价值变动

       3.可供出售金融资产公允价值变动损益

  4.金融资产重分类计入其他综合收益的金额

           5.持有至到期投资重分类为可供出
售金融资产损益

           6.其他债权投资信用减值准备

           7.现金流量套期储备

           8.外币财务报表折算差额                   -2,305,889.85                     -1,650,205.61

           9.其他


                                                                                                 17
                                                          桂林莱茵生物科技股份有限公司 2019 年第一季度报告全文


  归属于少数股东的其他综合收益的税后净


七、综合收益总额                                                  8,337,439.46                    16,635,771.53

     归属于母公司所有者的综合收益总额                             8,403,567.90                    16,641,471.67

     归属于少数股东的综合收益总额                                   -66,128.44                        -5,700.14

八、每股收益:

     (一)基本每股收益                                                      0.02                          0.04

     (二)稀释每股收益                                                      0.02                          0.04

本期发生同一控制下企业合并的,被合并方在合并前实现的净利润为:元,上期被合并方实现的净利润为:元。


法定代表人:秦本军                       主管会计工作负责人:郑辉                     会计机构负责人:张为鹏


4、母公司利润表

                                                                                                       单位:元

                 项目                           本期发生额                           上期发生额

一、营业收入                                                 74,539,563.72                        70,500,914.60

     减:营业成本                                            55,570,169.98                        57,360,363.44

         税金及附加                                                                                  35,275.43

         销售费用                                             1,268,268.58                         1,599,158.71

         管理费用                                             6,376,689.14                         4,688,778.64

         研发费用                                             2,280,986.86                         1,955,615.95

         财务费用                                             8,060,306.88                         5,473,407.60

               其中:利息费用                                 4,431,949.11                         1,878,333.33

                     利息收入                                   42,074.60                            25,595.75

         资产减值损失                                           -13,043.59                           -48,801.09

         信用减值损失

     加:其他收益                                              100,330.50                           449,507.00

       投资收益(损失以“-”号填列)                          465,472.35

         其中:对联营企业和合营企
业的投资收益

净敞口套期收益(损失以“-”号填列)

公允价值变动收益(损失以“-”号填
列)

  资产处置收益(损失以“-”号填列)

二、营业利润(亏损以“-”号填列)                            1,561,988.72                          -113,377.08



                                                                                                             18
                                      桂林莱茵生物科技股份有限公司 2019 年第一季度报告全文


     加:营业外收入                        11,765.89                            13,060.40

     减:营业外支出

三、利润总额(亏损总额以“-”号填
                                        1,573,754.61                           -100,316.68
列)

     减:所得税费用                       234,106.65

四、净利润(净亏损以“-”号填列)      1,339,647.96                           -100,316.68

     (一)持续经营净利润(净亏损
                                        1,339,647.96                           -100,316.68
以“-”号填列)

     (二)终止经营净利润(净亏损
以“-”号填列)

五、其他综合收益的税后净额

     (一)不能重分类进损益的其他
综合收益

  1.重新计量设定受益计划变动额

2.权益法下不能转损益的其他综合收


3.其他权益工具投资公允价值变动

  4.企业自身信用风险公允价值变动

             5.其他

(二)将重分类进损益的其他综合收


1.权益法下可转损益的其他综合收益

     2.其他债权投资公允价值变动

3.可供出售金融资产公允价值变动损


4.金融资产重分类计入其他综合收益
的金额

5.持有至到期投资重分类为可供出售
金融资产损益

         6.其他债权投资信用减值准备

             7.现金流量套期储备

             8.外币财务报表折算差额

             9.其他

六、综合收益总额                        1,339,647.96                           -100,316.68

七、每股收益:

     (一)基本每股收益                         0.00                                  0.00



                                                                                        19
                                                桂林莱茵生物科技股份有限公司 2019 年第一季度报告全文


    (二)稀释每股收益                                     0.00                                  0.00


5、合并现金流量表

                                                                                             单位:元

             项目                  本期发生额                             上期发生额

一、经营活动产生的现金流量:

    销售商品、提供劳务收到的现金                155,077,856.14                         217,935,124.77

客户存款和同业存放款项净增加额

    向中央银行借款净增加额

向其他金融机构拆入资金净增加额

  收到原保险合同保费取得的现金

    收到再保险业务现金净额

    保户储金及投资款净增加额

    处置以公允价值计量且其变动
计入当期损益的金融资产净增加额

    收取利息、手续费及佣金的现金

    拆入资金净增加额

    回购业务资金净增加额

    代理买卖证券收到的现金净额

    收到的税费返还                                9,661,394.77                           6,371,149.25

  收到其他与经营活动有关的现金                    3,491,857.99                           1,151,373.88

经营活动现金流入小计                            168,231,108.90                         225,457,647.90

    购买商品、接受劳务支付的现金                216,279,153.00                         147,711,249.14

    客户贷款及垫款净增加额

存放中央银行和同业款项净增加额

  支付原保险合同赔付款项的现金

    为交易目的而持有的金融资产
净增加额

    拆出资金净增加额

    支付利息、手续费及佣金的现金

    支付保单红利的现金

支付给职工以及为职工支付的现金                   22,760,806.16                          16,954,734.27

    支付的各项税费                                4,820,765.66                          31,582,682.08

  支付其他与经营活动有关的现金                   14,408,441.61                          16,404,703.04




                                                                                                   20
                                    桂林莱茵生物科技股份有限公司 2019 年第一季度报告全文


经营活动现金流出小计                258,269,166.43                        212,653,368.53

经营活动产生的现金流量净额          -90,038,057.53                         12,804,279.37

二、投资活动产生的现金流量:

     收回投资收到的现金

     取得投资收益收到的现金

     处置固定资产、无形资产和其他
                                          6,000.00
长期资产收回的现金净额

     处置子公司及其他营业单位收
                                      3,960,000.00
到的现金净额

  收到其他与投资活动有关的现金

投资活动现金流入小计                  3,966,000.00

     购建固定资产、无形资产和其他
                                     14,053,525.32                         44,380,320.33
长期资产支付的现金

     投资支付的现金

     质押贷款净增加额

     取得子公司及其他营业单位支
付的现金净额

  支付其他与投资活动有关的现金

投资活动现金流出小计                 14,053,525.32                         44,380,320.33

投资活动产生的现金流量净额          -10,087,525.32                        -44,380,320.33

三、筹资活动产生的现金流量:

     吸收投资收到的现金

     其中:子公司吸收少数股东投资
收到的现金

     取得借款收到的现金             224,700,000.00                         50,000,000.00

     发行债券收到的现金

  收到其他与筹资活动有关的现金           21,102.48                         48,399,553.89

筹资活动现金流入小计                224,721,102.48                         98,399,553.89

     偿还债务支付的现金             100,000,000.00                         50,000,000.00

分配股利、利润或偿付利息支付的现
                                      4,814,602.88                          2,133,395.83


     其中:子公司支付给少数股东的
股利、利润

  支付其他与筹资活动有关的现金         200,000.00                          20,000,000.00

筹资活动现金流出小计                105,014,602.88                         72,133,395.83

筹资活动产生的现金流量净额          119,706,499.60                         26,266,158.06


                                                                                      21
                                                桂林莱茵生物科技股份有限公司 2019 年第一季度报告全文


四、汇率变动对现金及现金等价物的
                                                   -139,147.69                             -42,723.29
影响

五、现金及现金等价物净增加额                     19,441,769.06                          -5,352,606.19

    加:期初现金及现金等价物余额                 31,502,680.17                          28,363,535.31

六、期末现金及现金等价物余额                     50,944,449.23                          23,010,929.12


6、母公司现金流量表

                                                                                             单位:元

               项目                本期发生额                             上期发生额

一、经营活动产生的现金流量:

    销售商品、提供劳务收到的现金                 90,609,326.43                          56,481,803.64

    收到的税费返还                                9,661,394.77                           6,371,149.25

  收到其他与经营活动有关的现金                    3,159,220.91                            643,971.58

经营活动现金流入小计                            103,429,942.11                          63,496,924.47

    购买商品、接受劳务支付的现金                159,108,787.79                          89,849,975.28

支付给职工以及为职工支付的现金                   15,383,976.21                          11,080,686.23

    支付的各项税费                                3,329,053.54                           8,735,429.34

  支付其他与经营活动有关的现金                    8,269,666.36                           9,793,477.50

经营活动现金流出小计                            186,091,483.90                         119,459,568.35

经营活动产生的现金流量净额                      -82,661,541.79                         -55,962,643.88

二、投资活动产生的现金流量:

    收回投资收到的现金

    取得投资收益收到的现金

    处置固定资产、无形资产和其他
                                                      6,000.00
长期资产收回的现金净额

    处置子公司及其他营业单位收
                                                  3,960,000.00
到的现金净额

  收到其他与投资活动有关的现金

投资活动现金流入小计                              3,966,000.00

    购建固定资产、无形资产和其他
                                                 13,712,552.04                          40,638,172.57
长期资产支付的现金

    投资支付的现金                                 450,000.00

    取得子公司及其他营业单位支
付的现金净额

  支付其他与投资活动有关的现金



                                                                                                   22
                                                          桂林莱茵生物科技股份有限公司 2019 年第一季度报告全文


投资活动现金流出小计                                       14,162,552.04                         40,638,172.57

投资活动产生的现金流量净额                                -10,196,552.04                        -40,638,172.57

三、筹资活动产生的现金流量:

    吸收投资收到的现金

    取得借款收到的现金                                    224,700,000.00                         50,000,000.00

    发行债券收到的现金

  收到其他与筹资活动有关的现金                                 21,102.48                        118,000,000.00

筹资活动现金流入小计                                      224,721,102.48                        168,000,000.00

    偿还债务支付的现金                                    100,000,000.00                         50,000,000.00

    分配股利、利润或偿付利息支付
                                                            4,814,602.88                          2,133,395.83
的现金

  支付其他与筹资活动有关的现金                              9,920,000.00                         33,000,000.00

筹资活动现金流出小计                                      114,734,602.88                         85,133,395.83

筹资活动产生的现金流量净额                                109,986,499.60                         82,866,604.17

四、汇率变动对现金及现金等价物的
                                                              -58,786.53                             -7,195.15
影响

五、现金及现金等价物净增加额                               17,069,619.24                        -13,741,407.43

    加:期初现金及现金等价物余额                           26,431,171.35                         21,379,079.15

六、期末现金及现金等价物余额                               43,500,790.59                          7,637,671.72


二、财务报表调整情况说明

1、首次执行新金融工具准则、新收入准则、新租赁准则调整首次执行当年年初财务报表相关情况

√ 适用 □ 不适用
合并资产负债表
                                                                                                      单位:元

            项目               2018 年 12 月 31 日          2019 年 1 月 1 日               调整数

流动资产:

    货币资金                              31,589,704.19

    应收票据及应收账款                   112,578,842.98

               应收账款                  112,578,842.98

    预付款项                               3,138,758.12

    其他应收款                            16,870,718.32

         其中:应收利息                      221,540.08

    存货                               1,088,532,774.25



                                                                                                            23
                                               桂林莱茵生物科技股份有限公司 2019 年第一季度报告全文


    其他流动资产             39,109,647.13

流动资产合计               1,291,820,444.99

非流动资产:

    可供出售金融资产        179,721,550.03           不适用                         -175,761,954.08

    其他权益工具投资     不适用                          175,761,954.08              175,761,954.08

    投资性房地产               5,612,174.75

    固定资产                567,270,232.24

    在建工程                   3,928,468.46

    无形资产                 51,677,998.03

    长期待摊费用                  150,801.55

    递延所得税资产           19,316,374.27

    其他非流动资产             2,531,810.27

非流动资产合计              830,209,409.60

资产总计                   2,122,029,854.59

流动负债:

    短期借款                345,000,000.00

    应付票据及应付账款      469,414,187.84

    预收款项                   3,192,875.77

    应付职工薪酬               8,478,173.57

    应交税费                   8,605,545.39

    其他应付款               19,573,053.01

      其中:应付利息              577,130.20

一年内到期的非流动负债       11,001,272.68

    其他流动负债             13,295,080.82

流动负债合计                878,560,189.08

非流动负债:

    递延收益                128,878,863.99

    递延所得税负债                777,293.43

非流动负债合计              129,656,157.42

负债合计                   1,008,216,346.50

所有者权益:

    股本                    437,281,362.00

    资本公积                261,669,420.58

    其他综合收益               6,422,948.43



                                                                                                 24
                                                      桂林莱茵生物科技股份有限公司 2019 年第一季度报告全文


    盈余公积                         41,642,337.56

    未分配利润                      366,649,545.72

归属于母公司所有者权益
                                  1,113,665,614.29
合计

    少数股东权益                         147,893.80

所有者权益合计                    1,113,813,508.09

负债和所有者权益总计              2,122,029,854.59

调整情况说明
母公司资产负债表
                                                                                                  单位:元

           项目           2018 年 12 月 31 日           2019 年 1 月 1 日               调整数

流动资产:

    货币资金                         26,512,195.37

    应收票据及应收账款              168,288,721.61

               应收账款             168,288,721.61

    预付款项                          2,327,726.91

    其他应收款                      189,510,409.35

    存货                            524,173,657.21

    其他流动资产                     27,801,422.09

流动资产合计                        938,614,132.54

非流动资产:

    可供出售金融资产                179,256,481.73          不适用                         -175,761,954.08

    长期股权投资                     51,913,304.59

    其他权益工具投资            不适用                           175,761,954.08             175,761,954.08

    投资性房地产                      5,612,174.75

    固定资产                        397,160,753.51

    在建工程                          3,928,468.46

    无形资产                         50,957,898.03

    递延所得税资产                   21,004,299.35

    其他非流动资产                    2,531,810.27

非流动资产合计                      712,365,190.69

资产总计                          1,650,979,323.23

流动负债:

    短期借款                        345,000,000.00

    应付票据及应付账款              159,979,581.79


                                                                                                        25
                                                   桂林莱茵生物科技股份有限公司 2019 年第一季度报告全文


     预收款项                       1,107,413.15

     应付职工薪酬                   4,198,317.67

     应交税费                       3,830,137.16

     其他应付款                   12,044,282.45

       其中:应付利息                577,130.20

一年内到期的非流动负债            11,001,272.68

流动负债合计                     537,161,004.90

非流动负债:

     递延收益                    128,228,863.99

     递延所得税负债                  745,943.42

非流动负债合计                   128,974,807.41

负债合计                         666,135,812.31

所有者权益:

     股本                        437,281,362.00

     资本公积                    261,669,420.59

     盈余公积                     41,642,337.56

     未分配利润                  244,250,390.77

所有者权益合计                   984,843,510.92

负债和所有者权益总计            1,650,979,323.23

调整情况说明


2、首次执行新金融工具准则、新租赁准则追溯调整前期比较数据的说明

□ 适用 √ 不适用


三、审计报告

第一季度报告是否经过审计
□ 是 √ 否
公司第一季度报告未经审计。




                                                                                                    26
桂林莱茵生物科技股份有限公司 2019 年第一季度报告全文



             桂林莱茵生物科技股份有限公司




             法定代表人:

                                     秦本军

                             2019 年 4 月 25 日




                                                 27
数据加载中...
prevnext
手机查看股票